M&A

Bayer (BAYRY) Loses Bid Against Johnson & Johnson Prostate Drug Claims

Published on 4/18/2026

#BAYRY#JNJ#pharmaceuticals#legal#litigation
Bayer (BAYRY) Loses Bid Against Johnson & Johnson Prostate Drug Claims

AI Summary

A US judge rejected Bayer's (BAYRY) motion to block claims regarding Johnson & Johnson's (JNJ) prostate cancer drug. This ruling may affect Bayer's legal exposure related to similar product liabilities. The case underscores ongoing competitive pressures in the pharmaceutical sector, particularly regarding patent and claim disputes. Bayer's strategy and resource allocation may be impacted by this decision as they navigate the legal landscape.

Source: Read original article (opens in new tab)

Related News

CRH Completes Delisting from London Stock Exchange in October 2023
M&A

CRH Completes Delisting from London Stock Exchange in October 2023

Apr 20

Evoke (EVO) Stock Rises on Bally’s (BALY) Intralot Acquisition Talks
M&A

Evoke (EVO) Stock Rises on Bally’s (BALY) Intralot Acquisition Talks

Apr 20

MHI (7011) Shares Jump 4% After First Warship Export Deal Announcement
M&A

MHI (7011) Shares Jump 4% After First Warship Export Deal Announcement

Apr 20

Eagle Natrium LLC secures $200 million investment for expansion
M&A

Eagle Natrium LLC secures $200 million investment for expansion

Apr 20